Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Randomized, Open-label Study of Intravenous Iron Isomaltoside 1000 (Monofer®) as Mono Therapy (Without Erythropoiesis Stimulating Agents) in Comparison With Oral Iron Sulfate in Subjects With Non-myeloid Malignancies Associated With Chemotherapy Induced Anaemia (CIA)
Brief Summary: The purpose of this study is to compare the efficacy and safety of intravenous iron therapy with oral iron therapy in patients with cancer and chemotherapy induced anaemia.


Options:
A: Arm Label: Arm A (ibrutinib, rituximab); Type: EXPERIMENTAL; Interventions: Drug: Ibrutinib, Other: Laboratory Biomarker Analysis, Other: Pharmacogenomic Study, Other: Quality-of-Life Assessment, Biological: Rituximab | Arm Label: Arm B (rituximab, fludarabine phosphate, cyclophosphamide); Type: ACTIVE_COMPARATOR; Interventions: Drug: Cyclophosphamide, Drug: Fludarabine Phosphate, Other: Laboratory Biomarker Analysis, Other: Pharmacogenomic Study, Other: Quality-of-Life Assessment, Biological: Rituximab | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Arm B (rituximab, fludarabine phosphate, cyclophosphamide) | Intervention Type: DRUG; Name: Fludarabine Phosphate; Assigned to Arm(s): Arm B (rituximab, fludarabine phosphate, cyclophosphamide) | Intervention Type: DRUG; Name: Ibrutinib; Assigned to Arm(s): Arm A (ibrutinib, rituximab) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm A (ibrutinib, rituximab), Arm B (rituximab, fludarabine phosphate, cyclophosphamide) | Intervention Type: OTHER; Name: Pharmacogenomic Study; Assigned to Arm(s): Arm A (ibrutinib, rituximab), Arm B (rituximab, fludarabine phosphate, cyclophosphamide) | Intervention Type: OTHER; Name: Quality-of-Life Assessment; Assigned to Arm(s): Arm A (ibrutinib, rituximab), Arm B (rituximab, fludarabine phosphate, cyclophosphamide) | Intervention Type: BIOLOGICAL; Name: Rituximab; Assigned to Arm(s): Arm A (ibrutinib, rituximab), Arm B (rituximab, fludarabine phosphate, cyclophosphamide)
B: Arm Label: iron isomaltoside 1000; Type: EXPERIMENTAL; Interventions: Drug: iron isomaltoside 1000 | Arm Label: iron sulphate; Type: ACTIVE_COMPARATOR; Interventions: Drug: iron sulphate | Intervention Type: DRUG; Name: iron isomaltoside 1000; Assigned to Arm(s): iron isomaltoside 1000 | Intervention Type: DRUG; Name: iron sulphate; Assigned to Arm(s): iron sulphate
C: Arm Label: Darbepoetin alfa 500 mcg - Group A; Type: EXPERIMENTAL; Interventions: Drug: Darbepoetin alfa - 500mcg | Arm Label: Darbepoetin alfa 2.25 mcg/kg - Group B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Darbepoetin alfa - 2.25 mcg/kg | Intervention Type: DRUG; Name: Darbepoetin alfa - 2.25 mcg/kg; Assigned to Arm(s): Darbepoetin alfa 2.25 mcg/kg - Group B | Intervention Type: DRUG; Name: Darbepoetin alfa - 500mcg; Assigned to Arm(s): Darbepoetin alfa 500 mcg - Group A
D: Arm Label: EPO plus sustained iron dextran; Type: EXPERIMENTAL; Interventions: Drug: Erythropoietins (EPO), Drug: Sustained iron dextran supplementation | Arm Label: EPO plus aggressive iron dextran; Type: EXPERIMENTAL; Interventions: Drug: Erythropoietins (EPO), Drug: Aggressive iron dextran supplementation | Arm Label: Double EPO; Type: ACTIVE_COMPARATOR; Interventions: Drug: Erythropoietins (EPO) | Intervention Type: DRUG; Name: Erythropoietins (EPO); Assigned to Arm(s): EPO plus aggressive iron dextran, EPO plus sustained iron dextran | Intervention Type: DRUG; Name: Aggressive iron dextran supplementation; Assigned to Arm(s): EPO plus aggressive iron dextran | Intervention Type: DRUG; Name: Erythropoietins (EPO); Assigned to Arm(s): Double EPO | Intervention Type: DRUG; Name: Sustained iron dextran supplementation; Assigned to Arm(s): EPO plus sustained iron dextran

Answer: B